Skip to main content

Table 2 Organ transplant recipients: immunosuppressive therapy

From: Induced and pre-existing anti-polyethylene glycol antibody in a trial of every 3-week dosing of pegloticase for refractory gout, including in organ transplant recipients

Patient ID (age) Organs transplanted Immunosuppressive regimen Year initiated
203 (65 y) kidney Mycophenolate mofetil 500 mg QD 1995
207 (45 y) kidney Cyclosporine 175 mg BID; Azathioprine 100 mg QD 1994
208 (32 y) kidney + pancreas Mycophenolate mofetil 500 mg BID; Tacrolimus 2 mg BID 2000
211 (47 y) kidney + pancreas Cyclosporine 150 mg BID; Azathioprine 50 mg QD 1991
214 (55 y) kidney Cyclosporine 125 mg TID 1991
233 (41 y) kidney x 2 Cyclosporine 75 mg BID; Azathioprine 50 mg QD 1993*
238 (51 y) kidney Cyclosporine 50 mg BID; Mycophenolate mofetil 1000 mg BID 1999
  1. *Year of second kidney transplant. The regimen taken between 1988 (year of first kidney transplant) and 1993 was not recorded.